Tech Company Financing Transactions
Lantern Pharma Funding Round
Lantern Pharma closed a $3.7 million Series A financing round on 5/3/2017. Investors included Bios Partners, Green Park & Golf Ventures and private investors.
Transaction Overview
Company Name
Announced On
5/3/2017
Transaction Type
Venture Equity
Amount
$3,700,000
Round
Series A
Investors
Bios Partners (Lead Investor) (Stella Robertson)
Proceeds Purpose
The company will use the funds from the financing to continue development of its two lead drug candidates and further the advancement of its big data and Artificial Intelligence (AI) platform.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1920 McKinney Ave. 7th Floor
Dallas, TX 75201
USA
Dallas, TX 75201
USA
Phone
Website
Email Address
Overview
Lantern develops novel targeted cancer therapeutics. Lantern identifies, acquires and advances de-risked, value embedded drug leads towards clinical success for unmet cancer needs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Panna Sharma
Chief Financial Officer
David Margrave
Chief Scientific Officer
Kishor Bhatia
Co-Founder
Peter Nara
Browse more venture capital transactions:
Prev: 5/3/2017: AdvisorEngine venture capital transaction
Next: 5/3/2017: Twine Data venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs